AER 002

Drug Profile

AER 002

Alternative Names: AER-002; Aerolytic; Bikunin - Aerovance; Inter-alpha-trypsin inhibitor light chain; Pulmolytic; SPINT2; Urinary trypsin inhibitor

Latest Information Update: 06 Jan 2011

Price : $50

At a glance

  • Originator Bayer
  • Developer Aerovance
  • Class Anti-inflammatories
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes - Chronic obstructive pulmonary disease; Cystic fibrosis

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2011 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 06 Jan 2011 No development reported - Phase-II for Cystic fibrosis in Russia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top